Home Biosimilar Antibodies Immunology & Inflammation PD-1/PD-L1 null Durvalumab (anti-PD-L1) For research use only.
Not for use in humans.

Durvalumab (anti-PD-L1)

Synonyms: MEDI4736

Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.

Durvalumab (anti-PD-L1)

Click to purchase the isotype control of Durvalumab (anti-PD-L1)

Selleck's Durvalumab (anti-PD-L1) has been cited by 13 publications

1 Customer Reviews

Purity & Quality Control

Choose Selective PD-1/PD-L1 Inhibitors

Name Citation PD-1/PD-L1 interaction PD-1 PD-L1 PD-1/PD-L1 Others
GS-4224 0
INCB086550 0
BMS-1001 0
BMS-1166 5
PD-1/PD-L1 Inhibitor 3 12
BMS-1 11
BMS202 20
CA-170 (AUPM-170)
SR 0987 IL17,RORγt
Spartalizumab (anti-PD-1)
Camrelizumab (anti-PD-1)
AUNP-12
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description Durvalumab (anti-PD-L1) is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
Features Human IgG1
Targets
PD-L1/CD80 [1]
(HTRF assay)		 PD-1/PD-L1 interaction [1]
(HTRF assay)
0.04 nM 0.1 nM
In Vitro
In vitro

The labeled radioligand shows good affinity to high PD-L1 expression cells and could be blocked with excess unlabeled intact durvalumab.[1]
Cell Research:

The A549 and H460 cells were cultured in six-well plates (~106 cells/well) and divided into two groups. All of the wells were incubated with 5% BSA for blocking nonspecific binding. Group A was presaturated with 100-fold excess of unlabeled durvalumab to block the binding of 124I-Durva-F(ab′)2, and group B had only the medium added. After 30 min, 2 nM of 124I-Durva-F(ab′)2 was added to each group and incubated for 1 h at 37 °C in a cell incubator. After supernatant collection, the cells were lysed using 2 M of NaOH.
In Vivo
In vivo

The peak tumor uptake of 124I-Durva-F(ab’)2 was close to 124I-Durva, but much earlier (5.29±0.42% ID/g for 124I-Durva-F(ab’)2 at 12 h vs 5.18±0.73% ID/g for 124I-Durva at 48 h). Compared with 124I-Durva, an accelerated blood clearance was observed for 124I-Durva-F(ab’)2, allowing for a higher tumor-to-background ratio.[1]
Animal Research

Animal Models: H460 and A549 tumor-bearing mice
Dosages: 20 μCi
Administration: i.v.

Product Details

CAS No. 1428935-60-7
Isotype Human IgG1
Source CHO cells
Formulation 100 mM Pro-Ac, 20 mM Arg, pH 5.0
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.

Tags: buy Durvalumab (anti-PD-L1) | Durvalumab (anti-PD-L1) supplier | purchase Durvalumab (anti-PD-L1) | Durvalumab (anti-PD-L1) cost | Durvalumab (anti-PD-L1) manufacturer | order Durvalumab (anti-PD-L1) | Durvalumab (anti-PD-L1) distributor